Immune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh

Clinical and Vaccine Immunology

Volumn 20, Issue 6, 2013, Pages 780-788

  Leung, Daniel T ^a,b,c   Uddin, Taher ^a   Xu, Peng ^d   Aktar, Amena ^a   Johnson, Russell A ^a   Rahman, Mohammad Arif ^a   Alam, Mohammad Murshid ^a   Bufano, Meagan Kelly ^b   Eckhoff, Grace ^c   Wu Freeman, Ying ^b   Yu, Yanan ^b   Sultana, Tania ^a,b   Khanam, Farhana ^a   Saha, Amit ^a   Chowdhury, Fahima ^a   Khan, Ashraf I ^a   Charles, Richelle C ^b,c   LaRocque, Regina C ^b,c   Harris, Jason B ^b,c   Calderwood, Stephen B ^b,c   Kováč, Pavol ^d   Qadri, Firdausi ^a   Ryan, Edward T ^b,c,e   more..

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CHOLERA VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; O SPECIFIC POLYSACCHARIDE; UNCLASSIFIED DRUG;

ADOLESCENT; AGE; ANTIBODY RESPONSE; ARTICLE; BANGLADESH; CHILD; CHOLERA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNE RESPONSE; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; VIBRIO CHOLERAE; WILD TYPE;

ADOLESCENT; ANTIBODIES, BACTERIAL; BANGLADESH; CHILD; CHILD, PRESCHOOL; CHOLERA; CHOLERA VACCINES; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFANT; MALE; O ANTIGENS; VACCINES, INACTIVATED; VIBRIO CHOLERAE;

EID: 84878296603     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00035-13     Document Type: Article

References (52)

1. Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB. 2012. Cholera. Lancet 379:2466-2476.
2. Zuckerman JN, Rombo L, Fisch A. 2007. The true burden and risk of cholera: implications for prevention and control. Lancet Infect. Dis. 7:521-530. (Pubitemid 47079151)
3. Anonymous. 2009. Cholera: global surveillance summary, 2008. Wkly. Epidemiol. Rec. 84:309-324.
4. Deen JL, von Seidlein L, Sur D, Agtini M, Lucas ME, Lopez AL, Kim DR, Ali M, Clemens JD. 2008. The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. PLoS Negl. Trop. Dis. 2:e173. doi:10.1371/journal.pntd.0000173.
5. Anonymous. 2011. Cholera, 2010. Wkly. Epidemiol. Rec. 86:325-339.
6. Anonymous. 2012. Cholera, 2011. Wkly. Epidemiol. Rec. 87:289-304.
7. Anonymous. 2010. Cholera vaccines:WHOposition paper. Wkly. Epidemiol. Rec. 85:117-128.
8. Shin S, Desai SN, Sah BK, Clemens JD. 2011. Oral vaccines against cholera. Clin. Infect. Dis. 52:1343-1349.
9. Sinclair D, Abba K, Zaman K, Qadri F, Graves PM. 2011. Oral vaccines for preventing cholera. Cochrane Database Syst. Rev. 3:CD008603. doi:10.1002/14651858.CD008603.pub2.
10. Sur D, Kanungo S, Sah B, Manna B, Ali M, Paisley AM, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Rao R, Thu Van N, Han SH, Attridge S, Donner A, Ganguly NK, Bhattacharya SK, Nair GB, Clemens JD, Lopez AL. 2011. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl. Trop. Dis. 5:e1289. doi:10.1371/journal.pntd.0001289.
11. Qadri F, Mohi G, Hossain J, Azim T, Khan AM, Salam MA, Sack RB, Albert MJ, Svennerholm AM. 1995. Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1. Clin. Diagn. Lab. Immunol. 2:685-688.
12. Neoh SH, Rowley D. 1970. The antigens of Vibrio cholerae involved in the vibriocidal action of antibody and complement. J. Infect. Dis. 121:505-513.
13. Majumdar AS, Ghose AC. 1981. Evaluation of the biological properties of different classes of human antibodies in relation to cholera. Infect. Immun. 32:9-14. (Pubitemid 11156894)
14. Patel SM, Rahman MA, Mohasin M, Riyadh MA, Leung DT, Alam MM, Chowdhury F, Khan AI, Weil AA, Aktar A, Nazim M, Larocque RC, Ryan ET, Calderwood SB, Qadri F, Harris JB. 2012. Memory B cell responses to Vibrio cholerae O1 lipopolysaccharide are associated with protection against infection from household contacts of patients with cholera in Bangladesh. Clin. Vaccine Immunol. 19:842-848.
15. Leung DT, Rahman MA, Mohasin M, Patel SM, Aktar A, Khanam F, Uddin T, Riyadh MA, Saha A, Alam MM, Chowdhury F, Khan AI, Charles R, LaRocque R, Harris JB, Calderwood SB, Qadri F, Ryan ET. Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh. Clin. Vaccine Immunol. 19:690-698.
16. Johnson RA, Uddin T, Aktar A, Mohasin M, Alam MM, Chowdhury F, Harris JB, LaRocque RC, Bufano MK, Yu Y, Wu-Freeman Y, Leung DT, Sarracino D, Krastins B, Charles RC, Xu P, Kovac P, Calderwood SB, Qadri F, Ryan ET. 2012. Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera. Clin. Vaccine Immunol. 19:1712-1721.
17. Xu P, Alam MM, Kalsy A, Charles RC, Calderwood SB, Qadri F, Ryan ET, Kovac P. 2011. Simple, direct conjugation of bacterial O-SP-core antigens to proteins: development of cholera conjugate vaccines. Bioconjug. Chem. 22:2179-2185.
18. Saha A, Chowdhury MI, Bhuiyan MS, Khanam F, Sayeed MA, Svennerholm AM, Qadri F. 2012. Effects of undernutrition and parasitic load on immune response to oral cholera vaccine Dukoral in Bangladeshi children. Am. J. Trop. Med. Hyg. 87(5 suppl 1):14-15.
19. Ahmed T, Svennerholm AM, Al Tarique A, Sultana GN, Qadri F. 2009. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding. Vaccine 27:1433-1439.
20. Leung DT, Rahman MA, Mohasin M, Riyadh MA, Patel SM, Alam MM, Chowdhury F, Khan AI, Kalivoda EJ, Aktar A, Bhuiyan MS, LaRocque RC, Harris JB, Calderwood SB, Qadri F, Ryan ET. 2011. Comparison of memory B cell, antibody-secreting cell, and plasma antibody responses in young children, older children, and adults with infection caused by Vibrio cholerae O1 El Tor Ogawa in Bangladesh. Clin. Vaccine Immunol. 18:1317-1325.
21. Chowdhury F, Rahman MA, Begum YA, Khan AI, Faruque AS, Saha NC, Baby NI, Malek MA, Kumar AR, Svennerholm AM, Pietroni M, Cravioto A, Qadri F. 2011. Impact of rapid urbanization on the rates of infection by Vibrio cholerae O1 and enterotoxigenic Escherichia coli in Dhaka, Bangladesh. PLoS Negl. Trop. Dis. 5:e999. doi:10.1371/journal.pntd.0000999.
22. Qadri F, Wenneras C, Albert MJ, Hossain J, Mannoor K, Begum YA, Mohi G, Salam MA, Sack RB, Svennerholm AM. 1997. Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1. Infect. Immun. 65:3571-3576. (Pubitemid 27398109)
23. John M, Bridges EA, Miller AO, Calderwood SB, Ryan ET. 2002. Comparison of mucosal and systemic humoral immune responses after transcutaneous and oral immunization strategies. Vaccine 20:2720-2726. (Pubitemid 34597132)
24. Sur D, Lopez AL, Kanungo S, Paisley A, Manna B, Ali M, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Rao R, Nguyen TV, Donner A, Ganguly NK, Nair GB, Bhattacharya SK, Clemens JD. 2009. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 374:1694-1702.
25. van Loon FP, Clemens JD, Chakraborty J, Rao MR, Kay BA, Sack DA, Yunus M, Ali M, Svennerholm AM, Holmgren J. 1996. Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine 14:162-166. (Pubitemid 26072863)
26. Ali M, Emch M, Park JK, Yunus M, Clemens J. 2011. Natural cholera infection-derived immunity in an endemic setting. J. Infect. Dis. 204:912-918.
27. Harris JB, LaRocque RC, Chowdhury F, Khan AI, Logvinenko T, Faruque AS, Ryan ET, Qadri F, Calderwood SB. 2008. Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl. Trop. Dis. 2:e221. doi:10.1371/journal.pntd.0000221.
28. Saha D, LaRocque RC, Khan AI, Harris JB, Begum YA, Akramuzzaman SM, Faruque AS, Ryan ET, Qadri F, Calderwood SB. 2004. Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh. J. Infect. Dis. 189:2318-2322. (Pubitemid 38757206)
29. Clutterbuck EA, Oh S, Hamaluba M, Westcar S, Beverley PC, Pollard AJ. 2008. Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine. Clin. Vaccine Immunol. 15:182-193. (Pubitemid 352025528)
30. Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, Saha A, Al Tarique A, Seidlein LV, Park E, Killeen KP, Mekalanos JJ, Clemens JD, Sack DA, Study Group PXV. 2007. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine 25:231-238. (Pubitemid 44856084)
31. Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, Saha A, Alam MS, Zaman K, Seidlein LV, Park E, Killeen KP, Mekalanos JJ, Clemens JD, Sack DA, Peru-15 Study Group. 2005. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J. Infect. Dis. 192:573-579. (Pubitemid 41099305)
32. Saha A, Chowdhury MI, Khanam F, Bhuiyan MS, Chowdhury F, Khan AI, Khan IA, Clemens J, Ali M, Cravioto A, Qadri F. 2011. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine 29:8285-8292.
33. Alam MM, Riyadh MA, Fatema K, Rahman MA, Akhtar N, Ahmed T, Chowdhury MI, Chowdhury F, Calderwood SB, Harris JB, Ryan ET, Qadri F. 2011. Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera. Clin. Vaccine Immunol. 18:844-850.
34. Cadoz M. 1998. Potential and limitations of polysaccharide vaccines in infancy. Vaccine 16:1391-1395. (Pubitemid 28364673)
35. Rijkers GT, Sanders EA, Breukels MA, Zegers BJ. 1998. Infant B cell responses to polysaccharide determinants. Vaccine 16:1396-1400. (Pubitemid 28364674)
36. Laferriere C. 2011. The immunogenicity of pneumococcal polysaccharides in infants and children: a meta-regression. Vaccine 29:6838-6847.
37. Bossuyt X, Borgers H, Moens L, Verbinnen B, Meyts I. 2011. Age- and serotype-dependent antibody response to pneumococcal polysaccharides. J. Allergy Clin. Immunol. 127:1079-1080; author reply 1080-1081.
38. Barrett DJ, Ayoub EM. 1986. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin. Exp. Immunol. 63:127-134. (Pubitemid 16196411)
39. Schauer U, Stemberg F, Rieger CH, Buttner W, Borte M, Schubert S, Mollers H, Riedel F, Herz U, Renz H, Herzog W. 2003. Levels of antibodies specific to tetanus toxoid, Haemophilus influenzae type b, and pneumococcal capsular polysaccharide in healthy children and adults. Clin. Diagn. Lab. Immunol. 10:202-207. (Pubitemid 36314441)
40. Qadri F, Ahmed F, Karim MM, Wenneras C, Begum YA, Abdus Salam M, Albert MJ, McGhee JR. 1999. Lipopolysaccharide- and cholera toxin-specific subclass distribution of B-cell responses in cholera. Clin. Diagn. Lab. Immunol. 6:812-818. (Pubitemid 29529971)
41. Schur PH, Rosen F, Norman ME. 1979. Immunoglobulin subclasses in normal children. Pediatr. Res. 13:181-183. (Pubitemid 9141345)
42. Aksu G, Genel F, Koturoglu G, Kurugol Z, Kutukculer N. 2006. Serum immunoglobulin (IgG, IgM, IgA) and IgG subclass concentrations in healthy children: a study using nephelometric technique. Turk. J. Pediatr. 48:19-24. (Pubitemid 43349482)
43. Klein Klouwenberg P, Bont L. 2008. Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines. Clin. Dev. Immunol. 2008:628963. doi:10.1155/2008/628963.
44. Tarique AA, Kalsy A, Arifuzzaman M, Rollins SM, Charles RC, Leung DT, Harris JB, Larocque RC, Sheikh A, Bhuiyan MS, Saksena R, Clements JD, Calderwood SB, Qadri F, Kovac P, Ryan ET. 2012. Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice. Clin. Vaccine Immunol. 19:594-602.
45. Boutonnier A, Villeneuve S, Nato F, Dassy B, Fournier JM. 2001. Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid. Infect. Immun. 69:3488-3493. (Pubitemid 32332255)
46. Kossaczka Z, Shiloach J, Johnson V, Taylor DN, Finkelstein RA, Robbins JB, Szu SC. 2000. Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice. Infect. Immun. 68:5037-5043.
47. Hutter J, Pasetti MF, Sanogo D, Tapia MD, Sow SO, Levine MM. 2012. Naturally acquired and conjugate vaccine-induced antibody to Haemophilus influenzae type b (Hib) polysaccharide in Malian children: serological assessment of the Hib immunization program in Mali. Am. J. Trop. Med. Hyg. 86:1026-1031.
48. Hoppenbrouwers K, Lagos R, Swennen B, Ethevenaux C, Knops J, Levine MM, Desmyter J. 1998. Safety and immunogenicity of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphthe-ria- tetanus-pertussis (DTP) combination vaccine administered in a dual-chamber syringe to infants in Belgium and Chile. Vaccine 16:921-927. (Pubitemid 28276002)
49. Simon R, Tennant SM, Wang JY, Schmidlein PJ, Lees A, Ernst RK, Pasetti MF, Galen JE, Levine MM. 2011. Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis. Infect. Immun. 79:4240-4249.
50. Ahmed A, Li J, Shiloach Y, Robbins JB, Szu SC. 2006. Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children. J. Infect. Dis. 193:515-521. (Pubitemid 43202742)
51. Passwell JH, Ashkenzi S, Banet-Levi Y, Ramon-Saraf R, Farzam N, Lerner-Geva L, Even-Nir H, Yerushalmi B, Chu C, Shiloach J, Robbins JB, Schneerson R, Israeli Shigella Study Group. 2010. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine 28:2231-2235.
52. Passwell JH, Ashkenazi S, Harlev E, Miron D, Ramon R, Farzam N, Lerner-Geva L, Levi Y, Chu C, Shiloach J, Robbins JB, Schneerson R, Israel Shigella Study Group. 2003. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children. Pediatr. Infect. Dis. J. 22:701-706. (Pubitemid 36999646)